Navigation Links
Products containing specific probes for detecting alternative splice forms protected

ExonHit Therapeutics, today announced the grant of a major patent, US # 6,881,571, by the United States Patent and Trademark Office on microarray products allowing the specific detection of mRNAs produced by alternative splicing, covering microarrays optimised for the discovery of alternative RNA splicing events. The patent protects the probe configuration of a unique set of five oligonucleotides for the detection of each splice variant. There are many applications for this patent, including drug discovery, diagnostics, and compound screenings for efficacy or toxicity as well as screening patients for potential efficacy of therapeutics.

Alternative RNA Splicing is a critical step in the expression of most genes, which can result in the expression of several mRNAs encoding proteins with different functions from a single gene. Splicing events are implicated in numerous pathologies and can be altered by various stress events such as virus, toxic agents, and drug exposure.

The genome-wide patented probe configuration described in the patent is the basis for the microarrays in ExonHit's SpliceArray product line launched earlier this year. The genome profiling market is rapidly growing, and SpliceArrays are the only commercially available microarrays designed to detect alternative splicing. Current SpliceArray products include GPCR, Ion Channel, and Nuclear Receptor family SpliceArrays, as well as custom design services. An Apoptosis and Cytokine gene family array will be launched in the coming months. SpliceArrays are manufactured for ExonHit by Agilent Technologies.

The granting of this patent solidifies ExonHit's leadership in the field of expression profiling and positions the company as the only partner for the conception or use of gene profiling microarrays that include alternative RNA splicing. "The granting of these claims build on the company's core assets further expanding our IP position in the field of gene expression and profiling," sta ted Bruno Tocque, President and CEO, ExonHit Therapeutics. "This is a significant event for ExonHit as we have been quite successful in leveraging strategic assets in multiple arenas, including the therapeutic, diagnostic and research tool markets ?areas in which these claims will further increase our market share."


'"/>

Source:ExonHit


Related biology news :

1. Metal-containing compounds show promise as HIV weapon
2. Preventing a pandemic: Study suggests strategies for containing a flu outbreak
3. Rapid response was crucial to containing the 1918 flu pandemic
4. Scientists generate patient-specific stem cells, Science study says
5. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
6. Eating, body weight regulated by specific neurons
7. Tool developed to silence genes in specific tissues using RNAi
8. Gene-specific Ebola therapies protect non-human primates from lethal disease
9. Unique dual target specificity of kinase inhibitor key for success against cancer
10. Serotonin, acting in a specific brain region, promotes sleep in fruit flies
11. A new male-specific gene in algae unveils an origin of male and female
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
Breaking Biology Technology: